Journal
BIOMATERIALS
Volume 139, Issue -, Pages 187-194Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2017.06.003
Keywords
Tumor targeting; Drug release; Ultrasound; PLGA nanoparticles; Doxorubicin
Funding
- Wyss Institute for Biologically Inspired Engineering at Harvard University
- DoD Breast Cancer Innovator award [W81XWH-08-1-0659]
- DOD [W81XWH-10-1-0565]
- DoD Breast Cancer Breakthrough Award [W81XWH-15-1-0305]
Ask authors/readers for more resources
Here we describe injectable, ultrasound (US)-responsive, nanoparticle aggregates (NPAs) that disintegrate into slow-release, nanoscale, drug delivery systems, which can be targeted to selective sites by applying low-energy US locally. We show that, unlike microbubble based drug carriers which may suffer from stability problems, the properties of mechanical activated NPAs, composed of polymer nanoparticles, can be tuned by properly adjusting the polymer molecular weight, the size of the nanoparticle precursors as well as the percentage of excipient utilized to hold the NPA together. We then apply this concept to practice by fabricating NPAs composed of nanoparticles loaded with Doxorubicin (Dox) and tested their ability to treat tumors via ultrasound activation. Mouse studies demonstrated significantly increased efficiency of tumor targeting of the US-activated NPAs compared to PLGA nanoparticle controls (with or without US applied) or intact NPAs. Importantly, when the Dox-loaded NPAs were injected and exposed to US energy locally, this increased ability to concentrate nanoparticles at the tumor site resulted in a significantly greater reduction in tumor volume compared to tumors treated with a 20-fold higher dose of the free drug. (C) 2017 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available